PolyPid, which develops an antibiotic coating for bone repair, has delayed its IPO. The company had planned to raise as much as $24 million from its public offering.
The head of the cHealth innovation fund Haim Horowitz told Globes that the delay was due to a change in the current environment for IPOs. The company hopes to try it next year instead when it feels that it will be able to raise more capital.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Based in Petah Tikva, Israel, PolyPid describes itself as an emerging clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), is proprietary drug delivery technology. The company boasts that PLEX is able to securely encapsulate many types of drugs, including proteins, to enable targeted, localized drug delivery into the body over periods of time ranging from days to several months.
The PLEXTM platform is a matrix made of thousands of alternating layers of polymers and lipids that entrap a therapeutic drug between them in order to form a protected reservoir that enables an effective localized drug delivery in the body. PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months. The application of our PLEX technology in our products enables us to optimize drug treatment regimens by predetermining release rates and durations, a rare combination of attributes.
PolyPid also has two lead candidates for use with bone transplants, BonyPid-1000 and BonyPid-500.
BonyPid-1000 is a bone graft substitute based product intended for filling bone voids or defects. It resorbs and is replaced with bone during the healing process.
BonyPid-500 is intended for use as a bone grafting material to fill, augment or reconstruct periodontal or oral/maxillofacial defect, such as filling of periodontal/infrabony defects, ridge augmentation, filling of extraction sites, sinus lifts and filling of cystic cavities.
It is currently planning to hold clinical trials in the U.S and Canada next year and hopes to be able to market its products in Europe in 2017.
PolyPid plans to be listed on the NASDAQ under the symbol PLPD. It first filed confidentially on July 8, 2014.
